Susquehanna Fundamental Investments LLC Takes Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Susquehanna Fundamental Investments LLC purchased a new stake in Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 291,383 shares of the company's stock, valued at approximately $1,643,000. Susquehanna Fundamental Investments LLC owned about 0.34% of Verve Therapeutics at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Barclays PLC grew its stake in Verve Therapeutics by 139.8% during the 3rd quarter. Barclays PLC now owns 222,919 shares of the company's stock worth $1,079,000 after buying an additional 129,944 shares during the last quarter. Norges Bank purchased a new stake in Verve Therapeutics during the fourth quarter worth $441,000. Nisa Investment Advisors LLC raised its stake in shares of Verve Therapeutics by 465.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 42,781 shares of the company's stock worth $241,000 after buying an additional 35,214 shares during the last quarter. GAMMA Investing LLC grew its stake in Verve Therapeutics by 189.7% in the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock valued at $34,000 after acquiring an additional 3,964 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Verve Therapeutics by 1.9% in the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company's stock valued at $627,000 after purchasing an additional 2,093 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

Verve Therapeutics Trading Down 9.8 %

VERV stock traded down $0.51 during midday trading on Tuesday, reaching $4.65. The company had a trading volume of 803,400 shares, compared to its average volume of 1,785,855. Verve Therapeutics, Inc. has a 1 year low of $2.86 and a 1 year high of $9.31. The company has a 50 day moving average of $5.14 and a two-hundred day moving average of $5.95. The company has a market capitalization of $414.87 million, a P/E ratio of -1.90 and a beta of 1.82.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. The firm had revenue of $13.08 million during the quarter, compared to analysts' expectations of $3.94 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. On average, sell-side analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on VERV shares. Guggenheim boosted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a report on Tuesday, April 15th. Royal Bank of Canada cut their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. HC Wainwright raised their target price on Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, April 14th. Canaccord Genuity Group lifted their target price on Verve Therapeutics from $32.00 to $39.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Finally, Cantor Fitzgerald raised Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Verve Therapeutics has an average rating of "Buy" and an average price target of $25.75.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.